Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML. Pullarkat, V., Levis, M. J., Mannis, G. N., Strickland, S., Lin, T. L., Faderl, S., Chakravarthy, D., Chandrasekaran, V., Cheung, R., Erba, H. LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.7026
View details for Web of Science ID 000708120604074